Research & Education

Current Role of Immunotherapy for Lung Cancer

Thursday, June 25, 2015 at 9 p.m. ET - Recording Available
 Scott N. Gettinger, MD  
Scott N. Gettinger, MD
Associate Professor of Medicine 
Medical Oncology | Yale University School of Medicine 
Yale Comprehensive Cancer Center 
Thoracic ONcology Program - Developmental Therapeutics 
Smilow Cancer Hospital at Yale-New Haven 
 

Name of Reviewer(s): 

              

Fred Hirsch, MD, PhD –Speakers Bureau/Advisory Board: Astrazeneca, Genentech, BMS, Lilly and Abbvie.

Name of Planner(s): 

 

      Deb Whippen-Nothing to Disclose 

Name of Activity: 

 

Current Role of Immunotherapy for Lung Cancer

Date of Activity:

 

06/25/2015

Faculty/Speaker(s):

Financial DISCLOSURES

 

Scott N. Gettinger, MD - Consultant for Bristol Myers-Squibb

Franco Foti-Moderator -Nothing to Disclose

Type of Activity: 

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?

 Yes  

If yes, please list: Unrestricted grant from: Genentech, Celgene and Bristol-Meyers Squibb.

Registration is taken on a first-come first served basis, participation is limited.

In this special report, Dr. Scott Gettinger provides an in-depth look at the evolving role of immunotherapeutics in the clinical management of advanced non small cell lung cancer. The most recent data from the 2015 Annual Meeting of the American Society of Clinical Oncology will be highlighted. The current role of FDA-approved immunotherapeutic agents in nsclc treatment paradigms will be discussed, along with a review of promising agents that are being evaluated in major clinical studies.

After viewing this program attendees will:

  • Demonstrate different immunotherapeutic approaches against cancer
  • Explore current indications for immunotherapy in lung cancer
  • Recognize different patterns of response to immunotherapies
  • Address potential toxicities associated with immunotherapy

Following the presentation, there will be ample time for discussion and a question/answer session. Attendees will be able to submit questions and comments to Dr. Gettinger via internet chat.

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

Use the Time Zone Converter to determine the time in your location

DOWNLOAD RECORDING

CME INFO: 

Financial/Commercial Relationships DISCLOSURES

A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used, on patients that benefits the individual in any financial amount and therefore, may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. 

 This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/moderators/peer reviewers et. al. conflicts of interest  were identified, reviewed and resolved from all individuals involved in the development  or able to influence and control the content of this CME activity; IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners.  Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from any of IASLC CME activity presentation.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

 

CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GOAL & PURPOSE

The objective of this workshop is to provide an in-depth look at the evolving role of immunotherapeutics in the clinical management of advanced non small cell lung cancer. The most recent data from the 2015 Annual Meeting of the American Society of Clinical Oncology will be highlighted. The current role of FDA-approved immunotherapeutic agents in nsclc treatment paradigms will be discussed, along with a review of promising agents that are being evaluated in major clinical studies.

TARGET AUDIENCE

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

DISCLAMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Thank you for your participation. 

IASLC Financial/Commercial and Conflicts of Interest Policy

IASLC Honorarium Policy

Financial/Commercial Relationships Agreement (LOA)

Participants who complete a pre-and post-test along with an evaluation will receive 1 AMA PRA Category 1 CreditTM for each completed webinar. If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program. CME credit is only available to attendees of the live webinar.

This series is supported in part by unrestricted educational grants provided by Bristol-Myers Squibb Co., Genentech and Celgene.